Nicholas Guinn, MD
Family Medicine · Jonesboro, ARNPI 1710253208
Payments from drug & device makers
Across 572 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pfizer$1K
- AbbVie$889
- Novo Nordisk$777
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$394
- Boehringer Ingelheim$336
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,164100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,677 |
| Pfizer | 109 | $1,147 |
| AbbVie(2 entities) | 75 | $889 |
| Novo Nordisk | 61 | $777 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $394 |
| Boehringer Ingelheim | 27 | $336 |
| Lilly USA, LLC | 26 | $314 |
| GSK | 27 | $310 |
| Otsuka America Pharmaceutical, Inc. | 19 | $293 |
| Amgen | 19 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $239 |
| Merck | 22 | $233 |
| Abbott | 10 | $216 |
| Johnson & Johnson | 14 | $167 |
| Novartis | 8 | $120 |
| Idorsia Pharmaceuticals US Inc | 6 | $91 |
| Bayer | 5 | $74 |
| Astellas Pharma US Inc | 6 | $73 |
| Phathom Pharmaceuticals, Inc. | 8 | $71 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Sanofi-aventis U.S. LLC | 4 | $47 |
| Amarin Pharma, Inc. | 3 | $39 |
| Mylan Specialty L.p. | 3 | $36 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Almatica Pharma LLC | 2 | $28 |
| Genentech USA, Inc. | 2 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,184 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $71,621 |
| EliquisApixaban | 73 | $58,795 |
| JardianceEmpagliflozin | 56 | $56,783 |
| MounjaroTirzepatide | 36 | $47,876 |
| FarxigaDapagliflozin Propanediol | 50 | $44,979 |
| EntrestoSacubitril/Valsartan | 33 | $33,550 |
| XareltoRivaroxaban | 22 | $28,505 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $21,434 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $13,864 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,102 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $12,936 |
| JanuviaSitagliptin Phosphate | 22 | $12,928 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,738 |
| MyrbetriqMirabegron | 15 | $11,727 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $10,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $336 | $79,34896 claims |
| Novo NordiskOzempic | $777 | $71,62164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,677 | $60,43282 claims |
| PfizerEliquis | $1,147 | $58,79573 claims |
| Lilly USA, LLCMounjaro | $314 | $47,87636 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $310 | $38,13460 claims |
| NovartisEntresto | $120 | $33,55033 claims |
| MerckJanumet, Januvia, Belsomra | $233 | $33,29349 claims |
| Johnson & JohnsonXarelto | $167 | $28,50522 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $11,72715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Jonesboro
- Christopher BrownJonesboro$160K
- Wallace HokeJonesboro$16K
- Timothy ShownJonesboro$14K
- Randall CarltonJonesboro$13K
- Trent LambJonesboro$13K
- Jeffery BarberJonesboro$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.